Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 1;58(1):5-14.
doi: 10.2169/internalmedicine.1423-18. Epub 2018 Aug 24.

Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders

Kosaku Murakami  1 , Tsuneyo Mimori  1
Affiliations
Review

Recent Advances in Research Regarding Autoantibodies in Connective Tissue Diseases and Related Disorders

Kosaku Murakami et al. Intern Med. .

Abstract

Connective tissue diseases (CTDs), also known as systemic autoimmune diseases, involve a variety of autoantibodies against cellular components. An important factor regarding these autoantibodies is that each antibody is exclusively related to a certain clinical feature of the disease type, which may prove useful in clinical practice. Thus far, more than 100 types of autoantibodies have been found in CTDs, and most of their target antigens have been identified. Many of these autoantigens are enzymes or regulators involved in important cellular functions, such as gene replication, transcription, repair/recombination, RNA processing, and protein synthesis, as well as proteins that form complexes with RNA and DNA. This article reviews the autoantibodies for each CTD, along with an assessment of their clinical significance, and provides suggestions regarding their utilization for clinical practice.

Keywords: autoantibody; connective tissue disease.

PubMed Disclaimer

Conflict of interest statement

Author's disclosure of potential Conflicts of Interest (COI).

Tsuneyo Mimori: Honoraria, Chugai Pharmaceutical, Bristol-Myers Squibb and Mitsubishi-Tanabe Pharma; Research funding, Chugai Pharmaceutical, Pfizer Japan, Eisai, Mitsubishi-Tanabe Pharma, Astellas Pharma, Daiichi Sankyo, AYUMI Pharmaceutical Corporation and Nippon Kayaku.

References

    1. Rose HM, Ragan C, Pearce E, et al. . Differential agglutination of normal and sensitized sheep erythrocytes by sera of patients with rheumatoid arthritis. Proc Soc Exp Biol Med (New York, NY) 68: 1-6, 1948. - PubMed
    1. Aletaha D, Neogi T, Silman AJ, et al. . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62: 2569-2581, 2010. - PubMed
    1. Aletaha D, Neogi T, Silman AJ, et al. . 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69: 1580-1588, 2010. - PubMed
    1. Mimori T, Suganuma K, Tanami Y, et al. . Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc Natl Acad Sci USA 92: 7267-7271, 1995. - PMC - PubMed
    1. Despres N, Talbot G, Plouffe B, Boire G, Menard HA. Detection and expression of a cDNA clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J Clin Invest 95: 1891-1896, 1995. - PMC - PubMed